Newsroom

Actions

140522 PR VI BIOFLOW III EN

Actions

Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro

Industry’s First Hybrid Drug-Eluting Stent Shown to be Effective in Patients with B2/C Lesions






Please contact us if you require further information

${loading}